Clinical Trial: A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07508995) titled 'A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)' on March 30.

Brief Summary: This is an open-label, single-arm, phase II study which will assess the safety and efficacy of BGB16673 in combination with sonrotoclax as a time-limited approach for participants with treatment-naive CLL/SLL.

Study Start Date: Sept. 01, 2026

Study Type: INTERVENTIONAL

Condition: Chronic Lymphocytic Leukemia (CLL)

Intervention: DRUG: BGB-16673

Given by mouth

DRUG: BGB-11417

Given by mouth

Recruitment Status: NOT_YET...